On the surface, there appears to be a wide range of options in reproductive health products for women, but San Diego,-Calif. startup Dare Bioscience Inc. nevertheless sees that there are still big, obvious gaps in meeting consumers' needs.
Daré Bioscience On Prowl To Fill Gaps In Women's Sexual Health
Emerging Company Profile: The company applies its mid-stage in-licensing strategy to bring in novel products for female contraception and sexual arousal disorder.
More from Strategy
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.